



Section: 5. Medicines for neurological disorders > 5.1. Medicines for central nervous system disorders > 5.1.3. Medicines for parkinsonism

ATC codes: N04BA02

<b>Indication</b>	Parkinson disease	ICD11 code: 8A00.0Z
<b>INN</b>	Levodopa + carbidopa	
<b>Medicine type</b>	Chemical agent	
<b>List type</b>	Core	
<b>Formulations</b>	Oral > Solid: 100 mg + 10 mg tablet ; 250 mg + 25 mg tablet ; 100 mg + 25 mg tablet	
<b>EML status history</b>	First added in 1977 (TRS 615) Changed in 1979 (TRS 641) Changed in 1982 (TRS 685) Changed in 2003 (TRS 920) Changed in 2013 (TRS 985) Changed in 2021 (TRS 1035)	
<b>Sex</b>	All	
<b>Age</b>	Adolescents and adults	
<b>Therapeutic alternatives</b>	levodopa + benserazide (ATC codes: N04BA02)	
<b>Patent information</b>	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> .	
<b>Wikipedia</b>	Levodopa + carbidopa	
<b>DrugBank</b>	Levodopa Carbidopa	

### Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended benserazide be specified as a therapeutic alternative for the carbidopa component under the square box listing for levodopa + carbidopa on the EML.

